Pleiotropic effects of HMG-CoA reductase inhibitors

被引:0
|
作者
Nikos Werner
Georg Nickenig
Ulrich Laufs
机构
[1] Medizinische Klinik und Poliklinik,
[2] Innere Medizin III,undefined
[3] Universitätskliniken des Saarlandes,undefined
[4] 66421 Homburg/Saar,undefined
[5] Germany,undefined
[6] Tel.: +49-6841/16-3000,undefined
[7] Fax: +49-6841/16-3437,undefined
[8] E-Mail: Ulrich@Laufs.com,undefined
来源
关键词
Key words HMG CoA reductase inhibitiors – hypercholesterolemia – pleiotropic effects – review;
D O I
暂无
中图分类号
学科分类号
摘要
HMG CoA reductase inhibitiors (statins) have been shown to be effective lipid lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels. This review summarizes the current evidence and the molecular mechanisms of the direct effects of statins on plaque stability, inflammation, endothelial function, oxidative stress, thrombosis and stroke. Furthermore, recent data on the effects of statins on bone marrow, bone density and dementia are described. In summary, statins have emerged as a novel and powerful tool to study cardiovascular biology, including protein isoprenylation, small G protein function, leukocyte activity and endothelial progenitor cells. These pleiotropic properties of statins may have important clinical implications in addition to lowering serum cholesterol.
引用
收藏
页码:105 / 116
页数:11
相关论文
共 50 条
  • [1] Pleiotropic effects of HMG-CoA reductase inhibitors
    Werner, N
    Nickenig, G
    Laufs, U
    BASIC RESEARCH IN CARDIOLOGY, 2002, 97 (02) : 105 - 116
  • [2] Pleiotropic effects of the HMG-CoA reductase inhibitors
    Mihos, Christos G.
    Santana, Orlando
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2011, 4 : 261 - 271
  • [3] The pleiotropic effects of HMG-CoA reductase inhibitors - Their role in osteoporosis and dementia
    Waldman, A
    Kritharides, L
    DRUGS, 2003, 63 (02) : 139 - 152
  • [4] HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, 1985, 183 : 295 - 310
  • [5] HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    HASUMI, K
    NATURAL PRODUCT REPORTS, 1993, 10 (06) : 541 - 550
  • [6] HMG-COA REDUCTASE INHIBITORS
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1988, 40 (06): : 477 - 477
  • [7] Immunomodulatory effects of HMG-CoA reductase inhibitors
    Danesh, FR
    Anel, RL
    Zeng, LX
    Lomasney, J
    Sahai, A
    Kanwar, YS
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2003, 51 (03) : 139 - 148
  • [8] HMG-CoA reductase inhibitors
    Illingworth, DR
    Tobert, JA
    ADVANCES IN PROTEIN CHEMISTRY, VOL 56: DRUG DISCOVERY AND DESIGN, 2001, 56 : 77 - 114
  • [9] HMG-COA REDUCTASE INHIBITORS
    GRUNDY, SM
    JOURNAL OF INTERNAL MEDICINE, 1990, 228 (03) : 201 - 205
  • [10] HMG-CoA reductase inhibitors
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (01) : 77 - 78